RNA5SP129: A Potential Drug Target and Biomarker (G100873399)

Target Name: RNA5SP129

NCBI ID: G100873399

RNA5SP129

Other Name(s): RN5S129 | RNA, 5S ribosomal pseudogene 129

RNA5SP129: A Potential Drug Target and Biomarker

RNA5SP129 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and is involved in the development, maintenance, and progression of various diseases, including cancer. The discovery of RNA5SP129 as a potential drug target and biomarker has significant implications for the development of new treatments for these diseases.

The Cell Cycle as a Drug Target

The cell cycle is a critical process that regulates the growth, development, and progression of cells. It is during the cell cycle that proteins are synthesized, including proteins that play a crucial role in cell division and growth. RNA5SP129 is a key regulator of the cell cycle and is involved in the assembly and function of the microtubules, which are essential for cell division.

RNA5SP129 has been shown to play a critical role in the regulation of the cell cycle in various organisms, including humans. It is a key regulator of mitosis, the process by which a cell divides, and is required for the proper formation of the mitotic spindle, which pulls the chromosomes apart during cell division. RNA5SP129 has also been shown to play a critical role in the regulation of the G1 phase of the cell cycle, which is the phase of the cell cycle when the cell prepares for cell division.

RNA5SP129 has also been shown to be involved in the regulation of the G2 phase of the cell cycle, which is the phase of the cell cycle when the cell prepares for cell division. During the G2 phase, RNA5SP129 helps to ensure that the cell is ready for cell division by regulating the levels of the protein p21, which is a critical regulator of the cell cycle.

RNA5SP129 as a Biomarker

In addition to its role as a drug target, RNA5SP129 has also been identified as a potential biomarker for various diseases. The discovery of RNA5SP129 as a biomarker has significant implications for the development of new treatments for these diseases.

One of the main advantages of RNA5SP129 as a biomarker is its potential to be used as a target for small molecules. Small molecules are a common type of drug that can be used to treat various diseases, including cancer. By using RNA5SP129 as a target for small molecules, researchers can develop new treatments for these diseases.

RNA5SP129 has also been shown to be involved in the regulation of various signaling pathways, including the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cell growth, survival, and angiogenesis, and is a potential target for the development of new drugs for various diseases.

RNA5SP129 has also been shown to be involved in the regulation of the NF-kappa-B signaling pathway, which is involved in the regulation of inflammation and immune responses. The NF-kappa-B signaling pathway is a potential target for the development of new treatments for various inflammatory diseases.

Conclusion

RNA5SP129 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its role in the cell cycle and its involvement in various signaling pathways make it an attractive target for the development of new treatments for various diseases. Further research is needed to fully understand the role of RNA5SP129 as a drug target and biomarker, and to develop new treatments based on this discovery.

Protein Name: RNA, 5S Ribosomal Pseudogene 129

The "RNA5SP129 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNA5SP129 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets